1-3 of 3
zanubrutinib
Close
Sort by
Journal Articles

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, David Simpson, Gavin Cull, Javier Munoz, Tycel J. Phillips, Won Seog Kim, Simon Rule, Siminder Kaur Atwal, Rachel Wei, William Novotny, Jane Huang, Michael Wang, Judith Trotman
Journal: Blood Advances
Blood Adv (2021) 5 (12): 2577–2585.
https://doi.org/10.1182/bloodadvances.2020004074
Published: 2021
Includes: Supplemental data
Journal Articles

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin α IIb β 3 in mice and humans

Gasim Dobie, Fahd A. Kuriri, Musab M. A. Omar, Fehaid Alanazi, Ali M. Gazwani, Chloe P. S. Tang, Daniel Man-yuen Sze, Sasanka M. Handunnetti, Constantine Tam, Denise E. Jackson
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4298–4311.
https://doi.org/10.1182/bloodadvances.2019000640
Published: 2019
Includes: Supplemental data
Journal Articles

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Luise Goldmann, Rundan Duan, Thorsten Kragh, Georg Wittmann, Christian Weber, Reinhard Lorenz, Philipp von Hundelshausen, Michael Spannagl, Wolfgang Siess
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4021–4033.
https://doi.org/10.1182/bloodadvances.2019000617
Published: 2019
Includes: Supplemental data